HTA208 Outcomes of Benefit Reassessments of Orphan Drugs in Germany After Exceedance of the Lowered Sales Threshold of 30 Million Euros
Abstract
Authors
L Frick L Schoppmeyer M Glüsen H. Kielhorn-Schönermark M Schönermark
L Frick L Schoppmeyer M Glüsen H. Kielhorn-Schönermark M Schönermark
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now